Mast Therapeutics, Inc. | TalkMarkets

Latest Posts

Mast Therapeutics Inc. Announces 4Q And Full Year 2016 Financial & Operating Results

Article By: Smarter Analyst

Monday, March 6, 2017 5:54 PM EDT

Mast Therapeutics Inc. reported net loss for the fourth quarter of 2016 was $6.0 million, or $0.02 per share (basic and diluted), compared to a net loss of $10.2 million, or $0.06 per share (basic and diluted), for the same period in 2015.

In this article: MSTX

Read

2 More Triple Digit Winners In Biotech

Article By: Bret Jensen

Monday, February 16, 2015 5:43 AM EDT

The small cap biotech and biopharma complex has been very kind to everyone. Here are two more recommendations that have the signature Bret Jensen “X” factors that make up a great small cap biotech investment.

In this article: THLD, MSTX, AVNR, CRIS, ZIOP

Read